Tech Company Financing Transactions
Pluristyx Funding Round
Pluristyx closed a financing round on 7/28/2025. Investors included BioLife Solutions, BroadOak Capital Partners and private investors.
Transaction Overview
Company Name
Announced On
7/28/2025
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
BioLife Solutions (Lead Investor)
BroadOak Capital Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand inventory with new clinical grade cell lines incorporating its proprietary FailSafe and iACT engineering and hypoimmune genetic edits in its polyclonal, synthetic RNA reprogramed iPSCs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 Western Ave
Seattle, WA 98121
USA
Seattle, WA 98121
USA
Phone
Website
Email Address
Overview
Established in 2018 as an advanced therapy tools company, Pluristyx helps companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless support through CMC consulting, contract development services, and research- and clinical-grade Ready-to-Use (RTU�) and Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Fryer
Chief Operating Officer
Jason Carstens
Chief Technical Officer
Brian Hawkins
VP - Finance
James Laing
Browse more venture capital transactions:
Prev: 7/28/2025: Dropzone AI venture capital transaction
Next: 7/28/2025: DynaRisk venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs